STI-6129 not checked
Zhejiang ACEA Pharmaceutical Co. Ltd. · Sorrento Therapeutics, Inc. · Anti-CD38 antibody drug conjugate
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.”In the company’s words, NCT05565807 on ClinicalTrials.gov
- Tested for
- Relapsed or Refractory Multiple Myeloma
- Main trialPhase 1/2
- “This is a phase Ib/IIa, open-label, dose-escalation, and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.”In the company’s words, NCT05565807 on ClinicalTrials.gov
- Other names
- Anti-CD38 antibody drug conjugate
Other drugs for Relapsed or Refractory Multiple Myeloma
- DostarlimabGSK · Phase 3
- NiraparibGSK · Phase 3
- MezigdomideCelgene · Phase 3
- PlonmarlimabTJ Biopharma Co., Ltd. · Phase 3
- GumarontinibCSPC · Phase 2/3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
Coming up1
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Dec 2026 | Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | |
| Phase 1/2Unknown | Sep 2024 | Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis | |
| Phase 1/2Unknown | Dec 2025 | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | |
| Phase 1Withdrawn | Sep 2024 | An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis | |
| Phase 1Unknown | Aug 2025 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026